These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 26000300)
1. Smoldering multiple myeloma. Gao M; Yang G; Kong Y; Wu X; Shi J Biomed Res Int; 2015; 2015():623254. PubMed ID: 26000300 [TBL] [Abstract][Full Text] [Related]
2. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311 [TBL] [Abstract][Full Text] [Related]
3. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology. Mateos MV; Landgren O Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254 [TBL] [Abstract][Full Text] [Related]
4. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management. Hillengass J; Moehler T; Hundemer M Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683 [TBL] [Abstract][Full Text] [Related]
5. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial. Eythorsson E; Rognvaldsson S; Thorsteinsdottir S; Einarsson Long T; Reed ER; Sigurdardottir GA; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Sveinsdottir SV; Sigurdsson F; Thordardottir AR; Palsson R; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Sigurdsson J; Steingrimsdottir H; Hultcrantz M; Durie BGM; Harding S; Landgren O; Aspelund T; Love TJ; Kristinsson SY Ann Intern Med; 2024 Apr; 177(4):449-457. PubMed ID: 38560901 [TBL] [Abstract][Full Text] [Related]
12. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Pérez-Persona E; Vidriales MB; Mateo G; García-Sanz R; Mateos MV; de Coca AG; Galende J; Martín-Nuñez G; Alonso JM; de Las Heras N; Hernández JM; Martín A; López-Berges C; Orfao A; San Miguel JF Blood; 2007 Oct; 110(7):2586-92. PubMed ID: 17576818 [TBL] [Abstract][Full Text] [Related]
13. [Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma]. Jurczyszyn A; Olszewska-Szopa M; Skotnicki AB Przegl Lek; 2015; 72(11):642-8. PubMed ID: 27012123 [TBL] [Abstract][Full Text] [Related]
15. Advances in the management of asymptomatic myeloma. Mateos MV Curr Opin Oncol; 2014 Nov; 26(6):670-6. PubMed ID: 25210868 [TBL] [Abstract][Full Text] [Related]
16. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. Rajkumar SV Hematology Am Soc Hematol Educ Program; 2005; ():340-5. PubMed ID: 16304401 [TBL] [Abstract][Full Text] [Related]
17. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study. Golombick T; Diamond TH; Manoharan A; Ramakrishna R Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182 [TBL] [Abstract][Full Text] [Related]
18. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells. Sezer O; Heider U; Zavrski I; Possinger K Haematologica; 2001 Aug; 86(8):837-43. PubMed ID: 11522540 [TBL] [Abstract][Full Text] [Related]
19. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity. Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394 [TBL] [Abstract][Full Text] [Related]